Envestnet Asset Management
MBRX icon

Envestnet Asset Management’s Moleculin Biotech MBRX Stock Holding History

Envestnet Asset Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-29
Closed -$12K – 4012
2022
Q3 		$12K Buy
+29
New +$16.8K ﹤0.01% 3882
2022
Q2 		– Sell
-28
Closed -$19K – 4005
2022
Q1 		$19K Buy
+28
New +$16.1K ﹤0.01% 3902

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Envestnet Asset Management's MBRX Position: Q4 2022 in Review

Envestnet Asset Management sold out of Moleculin Biotech (MBRX) in Q4 2022, closing a stake of 29 shares — an estimated $12K sold.

Envestnet Asset Management first reported a position in MBRX in Q1 2022 and held it in 2 quarters. The position peaked at $19K in Q1 2022. 22 funds tracked by Wall St. Rank hold MBRX as of Q4 2022.

  • Envestnet Asset Management reported no remaining Moleculin Biotech position as of Q4 2022 after selling out during the quarter.
  • Envestnet Asset Management sold 29 Moleculin Biotech shares in Q4 2022, an estimated $12K.
  • Envestnet Asset Management first reported a position in Moleculin Biotech in Q1 2022 and held it in 2 quarters.
  • Envestnet Asset Management's Moleculin Biotech position peaked at $19K in Q1 2022.
  • 22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2022.

Based on Envestnet Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.